Clinical Trials Browser

Phase 1/2 × Celecoxib × Breast × Clear all

NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1/2 Terminated

Triple Negative Breast Neoplasms

NCT01425476 2017-08-09

Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors

Phase 1/2 Completed

Breast Neoplasms

NCT01769625 2017-08-09

Changes in Biomarkers Using Prostaglandin Inhibitors

Phase 1/2 Completed

Biomarker Change Linked to Breast Cancer